Drug Profile
TP 113
Alternative Names: TP-113Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Thetis Pharmaceuticals
- Class Biguanides; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Type 2 diabetes mellitus in USA (PO) (Thetis Pharmaceuticals pipeline, August 2023)
- 28 May 2019 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 12 Aug 2015 Thetis Pharmaceuticals has patent protection for TP 113 in USA (Thetis Pharmaceuticals website, August 2015)